Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review
暂无分享,去创建一个
K. Lobner | Michael R Ehmann | J. Hinson | J. Niforatos | K. Balhara | P. Weygandt | Lukas Ramcharran | Michael R. Ehmann
[1] J. Parissis,et al. The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature , 2022, European heart journal supplements : journal of the European Society of Cardiology.
[2] T. Shiga. Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure , 2022, European heart journal supplements : journal of the European Society of Cardiology.
[3] Tammy T Nguyen,et al. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. , 2022, The American journal of emergency medicine.
[4] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[5] D. Carrié,et al. Successful Reversal of Severe Tachycardia-Induced Cardiomyopathy with Cardiogenic Shock by Urgent Rhythm or Rate Control: Only Rhythm and Rate Matter , 2021, Journal of clinical medicine.
[6] D. Harrison,et al. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review , 2021, Critical Care.
[7] J. Healey,et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. , 2020, The Canadian journal of cardiology.
[8] Roger Suss. Guideline groups should not make recommendations when there is considerable uncertainty , 2020, Canadian Medical Association Journal.
[9] Julian Pt Higgins,et al. Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments , 2020, Research synthesis methods.
[10] R. Sinert,et al. Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis. , 2020, Annals of emergency medicine.
[11] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[12] E. Belley‐Cote,et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review , 2019, Intensive Care Medicine.
[13] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.
[14] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.
[15] G. Peksa,et al. Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction☆,☆☆ , 2019, The American journal of emergency medicine.
[16] M. Jandali. Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation , 2018, Clinical Drug Investigation.
[17] J. Healey,et al. Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation , 2018 .
[18] M. Hernán,et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.
[19] J. Healey,et al. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. , 2016, The Canadian journal of cardiology.
[20] J. Piccini,et al. Atrial fibrillation in heart failure: what should we do? , 2015, European heart journal.
[21] R. Califf,et al. Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial , 2015, Journal of the American Heart Association.
[22] B. Rowe,et al. Emergency Department Patients With Atrial Fibrillation or Flutter and an Acute Underlying Medical Illness May Not Benefit From Attempts to Control Rate or Rhythm. , 2015, Annals of emergency medicine.
[23] M. Giudici,et al. EFFICACY AND SAFETY OUTCOMES OF VARIOUS RATE CONTROL STRATEGIES FOR PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION AND ATRIAL FIBRILLATION OR FLUTTER WITH RAPID VENTRICULAR RESPONSE , 2015 .
[24] Hugh Calkins,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.
[25] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[26] Deepak L. Bhatt,et al. Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure: An Analysis of Get With The Guidelines–Heart Failure , 2012, Circulation. Heart failure.
[27] S. Evans. Clinical trial structures. , 2010, Journal of experimental stroke & translational medicine.
[28] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[29] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[30] Amin Daoulah,et al. Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation. , 2007, The American journal of cardiology.
[31] M. Rich,et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.
[32] L. Tamariz,et al. Pharmacological rate control of atrial fibrillation. , 2004, Cardiology clinics.
[33] A. Manolis,et al. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. , 2001, International journal of cardiology.
[34] Marlene R. Miller,et al. The evidence regarding the drugs used for ventricular rate control. , 2000, The Journal of family practice.
[35] J. Grimshaw,et al. Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.
[36] W. Lewis,et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. , 1994, The American journal of cardiology.
[37] A. Zbrozek,et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. , 1993, The American journal of cardiology.